Tharimmune Inc., a clinical-stage biotechnology company, has announced plans to initiate a first-in-human clinical trial for its promising therapeutic candidate, TH023, within the next 12 months. TH023 is being developed as an innovative oral antibody medication targeting inflammation. This upcoming trial follows positive preclinical results and signifies a significant step in bringing this potential treatment to patients. The company is currently optimizing the formulation and dosing regimen of TH023 in preparation for the trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.